Collection of Peripheral Blood Mononuclear Cells From Healthy Subjects

Not yet recruiting

• Conditions: Disease of the Blood

• Registration Number: NCT05560217
• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Brief Summary

In accordance with the selection criteria, component blood collection will be carried out and peripheral blood mononuclear cells will be isolated, cryopreserved and in vitro culture of peripheral blood mononuclear cells. Cultivating cells under normal culture conditions or potential drug molecule treatment, observing and recording key parameters such as cell viability, proliferation, apoptosis and functional gene expression, will also provide an important reference for the production of CAR-T cell drugs.

Detailed Description

aged 18-40, regardless of nationalities, and had no adverse reactions in blood donation; Weight: male≥50kg, female≥45kg, and 18.5kg/m2≤BMI≤30kg/m2 (BMI =weight（kg）÷height（m）2)；

Blood pressure:

12.0Kpa（90mmHg）≤systolic pressure\<18.7Kpa（140mmHg） 8.0Kpa（60mmHg）≤diastolic pressure\<12.0Kpa（90mmHg）； Pulse rate: 60 beats/ min \~ 100 beats/ min, the athlete with high-level stamina≥50 beats/ min, normal and tidy rhythm.

Body temperature:36.3-37.2℃; Generally in good condition: no impairment of major organs, including heart, lung, liver, and kidney, no serious or uncontrolled infections, and no history of severe mental illness;

The clinical lab tests must meet the following standards:

Blood routine, blood biochemistry, normal or abnormal liver and kidney function have no clinical significance; Normal testing of coagulation function; Negative for antibody to Hepatitis A Virus (HAV-IgM); Negative for Hepatitis B Virus Surface Antigen (HBsAg); Negative for antibody to Hepatitis C Virus (HCV); Negative for antibody to Human Immunodeficiency Virus (HIV-1 and HIV-2); Negative for Syphilis; Negative for DNA to Epstein-Barr Virus (EBV). Negative for DNA to cytomegalovirus (CMV) . Negative for DNA to B19. Negative for Human T Lymphocytic leukemia Virus (HTLV).

Study Timeline

• Status Verified: 2022-09
• Study First Submitted: 2022-09-26
• Study First Submitted QC: 2022-09-26
• Last Update Submitted: 2022-09-26
• Study First Posted: 2022-09-29
• Last Update Posted: 2022-09-29
• Study Start: 2022-10-10
• Primary Completion: 2025-09-10
• Study Completion: 2025-09-10

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• aged 18-40, regardless of nationalities, and had no adverse reactions in blood donation;
• Weight: male≥50kg, female≥45kg, and 18.5kg/m2≤BMI≤30kg/m2 (BMI =weight（kg）÷height（m）2)；
• Blood pressure:

12.0Kpa（90mmHg）≤systolic pressure<18.7Kpa（140mmHg） 8.0Kpa（60mmHg）≤diastolic pressure<12.0Kpa（90mmHg）； Pulse rate: 60 beats/ min ~ 100 beats/ min, the athlete with high-level stamina≥50 beats/ min, normal and tidy rhythm.

• Body temperature:36.3-37.2℃;
• Generally in good condition: no impairment of major organs, including heart, lung, liver, and kidney, no serious or uncontrolled infections, and no history of severe mental illness;
• The clinical lab tests must meet the following standards:

Blood routine, blood biochemistry, normal or abnormal liver and kidney function have no clinical significance; Normal testing of coagulation function; Negative for antibody to Hepatitis A Virus (HAV-IgM); Negative for Hepatitis B Virus Surface Antigen (HBsAg); Negative for antibody to Hepatitis C Virus (HCV); Negative for antibody to Human Immunodeficiency Virus (HIV-1 and HIV-2); Negative for Syphilis; Negative for DNA to Epstein-Barr Virus (EBV). Negative for DNA to cytomegalovirus (CMV) . Negative for DNA to B19. Negative for Human T Lymphocytic leukemia Virus (HTLV).

Exclusion Criteria

• You have diseases in respiratory, circulatory, digestive, urinary, blood, immune, endocrine system or metabolic disorders;
• You have neurological diseases, mental diseases, Creutzfeldt-Jakob disease and have a family medical history or those who have received treatment with tissues or tissue derivatives that may be infected by Creutzfeldt-Jakob pathogen;
• You have chronic skin diseases, especially infectious, allergic or inflammatory systemic skin diseases;
• You have allergic diseases or frequent relapse;
• You have/had malignant tumors or benign tumors cause health problems;
• You have an infectious disease, a carrier of an infectious disease, a suspected infectious disease;
• You have allogeneic tissue organ graft recipients.
• You have undergone the removal of important internal organs such as the stomach, kidneys, spleen, lungs and so on;
• Those who have caused the recipient to have infectious diseases related to blood transfusion.
• You have had minor surgery within 3 months, including appendectomy, eye surgery, etc.; major surgery within 1 year, such as: surgical treatment of gynecological benign tumor, superficial benign tumor, etc.;
• Women in pregnancy or had a miscarriage within 6 months, or post partum and in lactation within 1 year;
• Recovered from Upper respiratory tract infection no longer than one week, or from pneumonia no longer than three months;
• Recovered from Acute pyelonephritis no longer than 3 months, or within the attack period of the urinary tract stones;
• Injuries caused by or wounds contaminated by devices/apparatuses contaminated by blood or tissue fluid or tattooed within one year;
• You have received whole blood and blood component transfusion within 1 year;
• You have got the last vaccination of live attenuated vaccines within 2 weeks including measles, parotitis, or infantile paralysis, or got the last vaccination of live attenuated vaccines within 4 weeks including Rubella Vaccine, Rabies Vaccine for Human Use, Japanese Encephalitis Live Vaccine;
• You have accepted last immunization of Rabies Vaccine for Human Use after being bitten by an animal within 1 year;
• You have received the last vaccination of antitoxin or immune serum injection within 4 weeks, or got the last vaccination of hepatitis B human immunoglobulin within 1 year;
• You have been in a clinical trial within 6 months;
• You have clinical trial records within 3 months for the donation of WBC, plasma and platelet;
• You are evaluated by Investigator s as an unsuitable participant for this research.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exploratory research and process development of immunocytotherapy-related products.	September10 2025	Cultured cells under normal culture conditions or under the treatment of potential drug molecules, observe and record cell viability, proliferation, apoptosis, and functional expression.